Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
AVE 1330A
Known as:
AVE-1330A
, AVE1330A
National Institutes of Health
Create Alert
Related topics
Related topics
3 relations
Broader (3)
Azepines
Sulfuric Acid Esters
beta-Lactamase Inhibitors
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
E. Chahine
,
Mariette Sourial
,
R. Ortiz
The Consultant pharmacist : the journal of the…
2015
Corpus ID: 30259220
OBJECTIVE To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety…
Expand
Review
2014
Review
2014
Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections
P. Lagacé-Wiens
,
A. Walkty
,
J. Karlowsky
Core evidence
2014
Corpus ID: 9772640
Avibactam (NXL104, AVE1330A) is a semi-synthetic, non-β-lactam, β-lactamase inhibitor that is active against Ambler class A…
Expand
Review
2013
Review
2013
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
G. Zhanel
,
C. Lawson
,
+9 authors
J. Karlowsky
Drugs
2013
Corpus ID: 32700350
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler…
Expand
2004
2004
In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor.
A. Bonnefoy
,
C. Dupuis-Hamelin
,
+6 authors
M. Lampilas
The Journal of antimicrobial chemotherapy
2004
Corpus ID: 11381565
OBJECTIVES Production of beta-lactamases is the main mechanism of beta-lactam resistance in Gram-negative bacteria. Despite the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE